In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients
Abstract Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by excessive levels of platelets (PLT), white blood cells (WBC), and hematocrit (HCT). Givinostat (ITF2357) is a potent histone‐deacetylase inhibitor that showed a good safety/efficacy profile in PV patients durin...
Saved in:
Main Authors: | Elena M. Tosca (Author), Alessandro De Carlo (Author), Roberta Bartolucci (Author), Francesco Fiorentini (Author), Silvia Di Tollo (Author), Maurizio Caserini (Author), Maurizio Rocchetti (Author), Paolo Bettica (Author), Paolo Magni (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor Givinostat
by: Silvia Consalvi, et al.
Published: (2013) -
In Vitro-In Vivo Correlation (IVIVC) Population Modeling for the In Silico Bioequivalence of a Long-Acting Release Formulation of Progesterone
by: Elena M. Tosca, et al.
Published: (2021) -
Bilateral adrenal hemorrhage in polycythemia vera
by: Shruti Bhandari, et al.
Published: (2016) -
Persistent neutrophilia progressing to polycythemia vera
by: Smita Singh, et al.
Published: (2011) -
Platelet thromboxane inhibition by low‐dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation
by: Giovanna Petrucci, et al.
Published: (2022)